Patients with relapsed and refractory HL have an increased chance of cure with HDT and ASCT, which can be estimated at approximately 50-60%. All outcomes are better in late relapses and if ...

Non-transplant salvage therapy for low-risk relapsed/refractory pediatric classical Hodgkin lymphoma (cHL) had high rates of ...

Guillermo 'Memo' del Bosque passed away after battling a rare cancer for over 5 years. He died on Monday, April 7, at the age ...

And for many people with these cancers, like Laura, relapse scenarios are all too familiar. But treatment options for NHL are on the rise. Rising rates of non-Hodgkin's lymphoma in the U.S. are ...

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

Cancer Center have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient's likely response ...

In 1997, rituximab received approval for use by the United States Food and Drug Administration (US FDA) for the treatment of patients with relapsed low-grade non-Hodgkin lymphomas. It was the ...